Get the Stockscreener App
1.81
2.16%
-0.04
Fortress Biotech Inc stock is traded at $1.81, with a volume of 118.94K.
It is down -2.16% in the last 24 hours and down -0.55% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
See More
Previous Close:
$1.85
Open:
$1.82
24h Volume:
118.94K
Relative Volume:
0.60
Market Cap:
$53.52M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.1633
EPS:
-11.0849
Net Cash Flow:
$-129.56M
1W Performance:
-8.12%
1M Performance:
-0.55%
6M Performance:
-0.55%
1Y Performance:
-13.40%
1-Day Range:
$1.77
$1.84
1-Week Range:
$1.77
$1.99
52-Week Range:
$1.325
$2.36
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.81 | 54.70M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
What makes Fortress Biotech Inc. stock price move sharplyStock Portfolio Risk and Return Analysis - Newser
What catalysts could drive Fortress Biotech Inc. stock higher in 2025Chart Pattern Updates For Fast Growth - jammulinksnews.com
Should I hold or sell Fortress Biotech Inc. stock in 2025Advanced Screener Ideas For Every Investor - jammulinksnews.com
What are analysts’ price targets for Fortress Biotech Inc. in the next 12 monthsWealth Building Data Feed For Every Investor - jammulinksnews.com
Why is Fortress Biotech Inc. stock attracting strong analyst attentionExpert Picks Review With Low Risk - jammulinksnews.com
How many analysts rate Fortress Biotech Inc. as a “Buy”Free Stock Review Backed By Experts - jammulinksnews.com
How strong is Fortress Biotech Inc. company’s balance sheetStock Strategy Picks For 2025 - jammulinksnews.com
Statistical indicators supporting Fortress Biotech Inc.’s strengthFuture Growth Stock Forecasting Strategy - Newser
How Fortress Biotech Inc. stock performs during market volatilityRisk Aware Trading Ideas with Alert Levels - Newser
Multi factor analysis applied to Fortress Biotech Inc.Free Low Capital High Return Stock Plans - Newser
What is the risk reward ratio of investing in Fortress Biotech Inc. stockLow Risk Alerts Backed By Experts - jammulinksnews.com
How did FTAIO's Q4 2024 earnings surprise impact its annual performance? - AInvest
Key External Factors That Drive Fortress Biotech Inc. Stock Price MovementsFree Consistent Profit Pattern Recognition Tools - Newser
How to build a custom watchlist for Fortress Biotech Inc.Buy and Hold Position Summary Review - Newser
Why Fortress Biotech Inc. stock is on top investor watchlistsAI Generated Buy/Sell Signal Forecast - Newser
Will Fortress Biotech Inc. stock split in the near futureMinimal Risk Growth Investment Opportunity Analysis - Newser
Why Fortress Biotech Inc. stock attracts strong analyst attentionStrategy Chart for Real-Time Trade Flow - Newser
Relative strength of Fortress Biotech Inc. in sector analysisLow Volatility Stable Growth Picks Rank High - metal.it
Detecting price anomalies in Fortress Biotech Inc. with AIPredicted Market Direction Based on Momentum - Newser
Trendlines Suggest Fortress Biotech Inc. May Bottom Out SoonOptimized Watchlist With Daily Adjustments Launched - metal.it
How high can Fortress Biotech Inc. stock goTrend Reversal Probability Forecast Update - Newser
Is Fortress Biotech Inc. reversing from oversold territoryStable Profit Zone and Loss Control Analysis - Newser
How did Fortress Priority C's revenue and expenses perform in Q4 2024? - AInvest
Published on: 2025-07-29 09:09:47 - beatles.ru
What are the technical indicators suggesting about Fortress Biotech Inc.Record-setting profit potential - jammulinksnews.com
How does Fortress Biotech Inc. compare to its industry peersTriple-digit returns - jammulinksnews.com
When is Fortress Biotech Inc. stock expected to show significant growthAccelerated financial growth - jammulinksnews.com
Intrinsic Value of Fortress Biotech Inc. Stock: Is It Undervalued or OvervaluedDaily Top Gainers - metal.it
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fortress Biotech Inc Stock (FBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN |
Sep 23 '24 |
Buy |
1.84 |
763,359 |
1,404,581 |
3,657,264 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):